A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib

被引：3

作者：

Gunaldi, Meral ^{[1
]}

Kara, Ismail Oguz ^{[1
]}

Duman, Berna Bozkurt ^{[1
]}

Afsar, Cigdem Usul ^{[1
]}

Ergin, Melek ^{[2
]}

Avci, Arbil ^{[2
]}

机构：

[1] Cukurova Univ, Fac Med, Dept Med Oncol, TR-01330 Saricam Adana, Turkey

[2] Cukurova Univ, Fac Med, Dept Pathol, TR-01330 Saricam Adana, Turkey

来源：

CANCER RESEARCH AND TREATMENT | 2014年 / 46卷 / 04期

关键词：

Extra-adrenal paraganglioma; Neoplasm metastasis; Sorafenib; Pheochromocytomas; Tyrosine kinase inhibitor; MALIGNANT PHEOCHROMOCYTOMA; SUNITINIB; TUMORS;

D O I：

10.4143/crt.2013.093

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Paragangliomas are relatively rare chromaffin cell tumors which may be cured through resection. Patients with paragangliomas may develop metastatic diseases. There is no consensus regarding refractory chemotherapy for treatment of metastatic disease. In this report, we presented a case of a 43-year-old woman who was admitted to the hospital with a history of episodic headaches, diaphoresis, and weakness. Elevated plasma catecholamine levels and a right paraaortic mass were observed on computed tomography. The mass was excised, and a diagnosis of paraganglioma was confirmed. After 20 months of follow-up, local recurrence and metastases were detected in the thorax, abdomen, and skeletal system. Plasma and urinary catecholamine levels were high. Chemotherapy was administered, and no improvement was observed. Therefore, following this palliative conventional chemotherapy, sorafenib was administered for three months, and, finally, positron emission tomography showed that the patient's lesions had completely regressed.

引用

页码：411 / 414

页数：4

共 13 条

[1] Metastatic paraganglioma and treatment with sunitinib: a case report [J].

Cirillo, Fernando .

TUMORI JOURNAL, 2010, 96 (06) :1022-1027

[2] Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001) [J].

Druce, M. R. ;

Kaltsas, G. A. ;

Fraenkel, M. ;

Gross, D. J. ;

Grossman, A. B. .

HORMONE AND METABOLIC RESEARCH, 2009, 41 (09) :697-702

[3] Metastatic Paraganglioma [J].

Fliedner, Stephanie M. J. ;

Lehnert, Hendrik ;

Pacak, Karel .

SEMINARS IN ONCOLOGY, 2010, 37 (06) :627-637

[4]

FRANKEL F, 1886, VIRCHOWS ARCH PATH A, V103, P244

[5] The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R [J].

Gross, DJ ;

Munter, G ;

Bitan, M ;

Siegal, T ;

Gabizon, A ;

Weitzen, R ;

Merimsky, O ;

Ackerstein, A ;

Salmon, A ;

Sella, A ;

Slavin, S .

[6] Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors [J].

Jimenez, Camilo ;

Cabanillas, Maria E. ;

Santarpia, Libero ;

Jonasch, Eric ;

Kyle, Karen L. ;

Lano, Elizabeth A. ;

Matin, Surena F. ;

Nunez, Rodolfo F. ;

Perrier, Nancy D. ;

Phan, Alexandria ;

Rich, Thereasa A. ;

Shah, Beejal ;

Williams, Michelle D. ;

Waguespack, Steven G. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (02) :386-391

[7] Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma [J].

Joshua, Anthony M. ;

Ezzat, Shereen ;

Asa, Sylvia L. ;

Evans, Andrew ;

Broom, Reuben ;

Freeman, Marc ;

Knox, Jennifer J. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (01) :5-9

[8]

Krawczyk A, 2010, ENDOKRYNOL POL, V61, P43

[9] Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors [J].

Kulke, MH ;

Stuart, K ;

Enzinger, PC ;

Ryan, DP ;

Clark, JW ;

Muzikansky, A ;

Vincitore, M ;

Michelini, A ;

Fuchs, CS .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) :401-406

[10]

Lehnert H, 2004, FRONT HORM RES, V31, P155

← 1 2 →